Abstract
The severity and type of clinical manifestations are variable in patients with cystic fibrosis (CF). The respiratory syndromes in these patients consist of lung infections associated with disseminated bronchiectasis (DB), asthma, and chronic obstructive pulmonary disease. To investigate the possible involvement of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in chronic pulmonary disease in adults, we studied 32 DB patients with a clinically isolated respiratory syndrome. Careful analysis of all the CFTR gene exons and their flanking regions revealed a significantly increased frequency of CFTR gene mutations in these patients. Thirteen CFTR gene mutations were identified in sixteen different alleles. Six of these mutations, which have previously been reported as CF defects, were found on nine alleles. A further four, two of which had not previously been described (D192N and 406-2 AΔC), are potentially disease-causing mutations. We also identified three rare substitutions (R31C, L997F, T1220I), which could be involved in mild CFTR gene disease. Four patients were compound heterozygotes, one carried two CFTR gene mutations (possibly allelic) and six were heterozygous for a mutation. These results indicate that CFTR gene mutations may play a role in bronchiectatic lung disease, possibly in a multifactorial context. These findings have implications for genetic counselling of DB patients and their families.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Di Sant’Agnese PA, Powell GF: The eccrine sweat defect in cystic fibrosis of the pancreas (mucoviscidosis). Ann NY Acad Sci 1962;93: 555–559.
Cystic Fibrosis Genetic Analysis Consortium: Cystic fibrosis mutation data, 1996.
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene: Genetic analysis. Science 1989;245: 1073–1080.
Rommens JM, Iannuzzi MC, Kerem B, Drum ML, Mehner G, Dean M, Rozmahel R, Cole J, Kennedy D, Hidaka N, Zsiga M, Buchwald M, Riordan JR, Tsui LC, Collins FS: Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 1989;245:1059–1065.
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drum ML, Iannuzzi MC, Collins FS, Tsui LC: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989;245: 1066–1073.
Dumur V, Gervais R, Rigot JM, Lafitte JJ, Manouvrier S, Biserte J, Mazeman M, Roussel P: Abnormal distribution of ΔF508 allele in azoospermic men with congenital aplasia of the epididymis and vas deferens. Lancet 1990;336: 512.
Rigot JM, Lafitte JJ, Dumur V, Gervais R, Manouvrier S, Biserte J, Mazeman E, Roussel P: Cystic fibrosis and congenital absence of the vas deferens. N Engl J Med 1991;325:64–65.
Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A: Congential bilateral absence of the vas deferens — A primarily genital form of cystic fibrosis. JAMA 1992;267:1794–1797.
Gervais R, Dumur V, Rigot JM, Lafitte JJ, Roussel P, Claustres M, Demaille J: High frequency of the R117H cystic fibrosis mutation in patients with congenital absence of the vas deferens. N Engl J Med 1993;328:447–457.
Osborne LR, Alton EWFW, Tsui L-C: CFTR intron 9 poly-T tract length in men with congenital bilateral absence of the vas deferens. Eighth Annual North American Cystic Fibrosis Conference, Orlando, 1994.
Culard J-F, Desgeorges M, Costa P, Laussei M, Razakatzara G, Navratil H, Demaille J, Claustres M: Analysis of the whole CFTR coding region and splice junctions in azoospermic men with congenital aplasia of epididymis or vas deferens. Hum Genet 1994;93:467–470.
Chillon M, Casals T, Mercier B, Brassas L, Lissens W, Silber S, Romey M, Ruiz-Romero J, Verlingue C, Claustres M, Nunes V, Férec C, Estivill X: Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475–1480.
Costes B, Girodon E, Ghanem N, Flori E, Jardin A, Soufir JC, Goossens M: Frequent occurrence of the CFTR intron 8 (TG)n5T allele in men with congenital bilateral absence of the vas deferens. Eur J Hum Genet 1995;3:285–293.
Mercier B, Verlingue C, Lissens W, Silber SJ, Novelli G, Bonduelle M, Audrézet MP, Férec C: Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients. Am J Hum Genet 1995;56:272–277.
Weiner Miller P, Hamosh A, Macek Jr M, Greenberger PA, MacLean J, Waiden SM, Slavin RG, Cutting GR: Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996;59:45–51.
Pignatti PF, Bombieri C, Marigo C, Benetazzo M, Luisetti M: Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet 1995;4: 635–639.
Fanen P, Ghanem N, Vidaud M, Besmond C, Martin J, Costes B, Plassa F, Goossens M: Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis transmembrane conductance regulator (CFTR) coding regions and splice site junctions. Genomics 1992; 13:770–776.
Costes B, Fanen P, Goossens M, Ghanem N: A rapid, efficient and sensitive assay for simultaneous analysis of multiple cystic fibrosis mutations. Hum Mutat 1993;2:185–191.
Gyllensten UB, Erlich HA: Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQα locus. Proc Natl Acad Sci USA 1988;85:7652–7656.
Highsmith WE, Burch LH, Boat TE, Spock A, Gorvoy J, Quittel L, Friedman KJ: A novel cystic fibrosis gene mutation is common in patients with normal sweat chloride concentrations. N Engl J Med 1994;331:974–980.
Kerem B, Zielenski J, Markiewicz D, Bozon D, Gazit E, Yahaf J, Kennedy D, Riordan J, Collins F, Rommens J, Tsui L-C: Identification of mutations in regions corresponding to the 2 putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci USA 1990;87:8447–8451.
Cutting GR, Kash LM, Rosenstein BJ, Zielenski J, Tsui L-C, Antonarakis SE, Kazazian HH Jr: A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature 1990;346:366–368.
Bozon D, Zielenski J, Rininsland F, Tsui LC: Identification of four new mutations in the cystic fibrosis transmembrane conductance regulator gene: I148T, L1077P, Y1092X, 2183 AA → G. Hum Mutat 1994;3:330–332.
Ghanem N, Costes B, Girodon E, Martin J, Fanen P, Goossens M: Identification of eight mutations and three sequence variations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1994;21: 434–436.
Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, Rommens J, Tsui L-C: Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991;10:214–228.
Kerem B, Kerem E: The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 1996;4:65–73.
Zielenski J, Markiewicz D, Chen HS, Schappert K, Seller A, Durie P, Corey M, Tsui LC: Identification of six mutations (R31L, 441delA, 681delC, 1461ins4, W1098R, E1104X) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Hum Mutat 1995;5:43–47.
Cuppens H, Teng H, Jaspers M, Wei L, Willems T, Jorrissen M, Van Poppel H, Nilius B, Cassiman JJ: The M470V polymorphic locus affects CFTR. Pediatr Pulmonol 1996;suppl 13:250.
Cuppens H, Cassiman JJ: Qualitative and quantitative effect of intragenic polymorphic loci on control and class I CFTR transcripts. Pediatr Pulmonol 1995;suppl 12:206.
Oates R, Amos J: Congenital bilateral absence of the vas deferens. A genetic commonality. World J Urol 1993;11:82–88.
Pignatti PF, Bombieri C, Benetazzo M, Casartelli A, Trabetti E, Gile LS, Martinati LC, Boner AL, Luisetti M: CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet 1996;58:889–892.
Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, Forstner J, Durie P, Nadeau J, Bear C, Tsui L-C: Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996;12:280–287.
Zielenski J, Rozmahel R, Corey M, Markiewicz D, Durie P, Tsui LC: Test for presence of modifier gene modulating CF disease severity on human chromosome 19q13. Pediatr Pulmonol 1996;suppl 13:251.
Higgins CF: The ABC of channel regulation. Cell 1995;82:693–696.
Acknowledgements
We thank Professor P. Reinert, Dr. M. Chery, Dr. E. Flori, Dr. Berrissoul and Dr. Do for providing the patients’ samples. This research was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Association Française de Lutte contre la Mucoviscidose (AFLM), and the Direction de la Recherche Clinique de l’Assistance Publique — Hôpitaux de Paris (DRC No. 940208).
Author information
Authors and Affiliations
Corresponding author
Additional information
The first two authors contributed equally to the work.
Rights and permissions
About this article
Cite this article
Girodon, E., Cazeneuve, C., Lebargy, F. et al. CFTR Gene Mutations in Adults with Disseminated Bronchiectasis. Eur J Hum Genet 5, 149–155 (1997). https://doi.org/10.1007/BF03405892
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1007/BF03405892
